Description of Research Expertise:
Dr. Brenner's primary expertise is in bioengineering and development of new technologies for the diseases of pulmonary & critical care medicine. He develops technologies at both the macro- and nano-scales, and technologies that synergistically combine the two scales. At the macro-scale, he has invented 3 medical devices that have formed the basis of funded companies, with one first-in-class device having attained FDA approval. His nano-scale technologies focus on targeted drug delivery and form the basis of his NIH-funded lab work.
His current device research focuses on developing devices to alleviate the dyspnea of patients with COPD (chronic obstructive pulmonary disease). His current drug delivery technology research utilizes nanotechnology-based carriers that deliver drugs to target specific organs. His drug carrier technology is focused on delivering drugs for 3 main diseases: ARDS (acute respiratory distress syndrome), stroke, and heart attack.
Brenner JS, Myerson J, Patel P, Muzykantov V: Nanocarriers to improve the diagnosis of ARDS American Thoracic Society International Conference : 2018.
Pan Daniel C, Myerson Jacob W, Brenner Jacob S, Patel Priyal N, Anselmo Aaron C, Mitragotri Samir, Muzykantov Vladimir: Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells. Scientific reports 8 (1): 1615,2018.
Brenner Jacob S, Kiseleva Raisa Yu, Glassman Patrick M, Parhiz Hamideh, Greineder Colin F, Hood Elizabeth D, Shuvaev Vladimir V, Muzykantov Vladimir R: The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). Pulmonary circulation 8 (1): 2045893217752329,2018.
Khoshnejad Makan, Brenner Jacob S, Motley William, Parhiz Hamideh, Greineder Colin F, Villa Carlos H, Marcos-Contreras Oscar A, Tsourkas Andrew, Muzykantov Vladimir R: Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9. Scientific reports 8 (1): 1760,2018.
Brenner JS, Pan D, Myerson J, Muzykantov V, et al: RBC-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude Nature Communications : In Press ,2018.
Brenner JS, Bhamidipati K, Glassman P, Ramakrishnan N, Jiang D, Paris AJ, Myerson JW, Pan DC, Shuvaev VV, Villa C, Hood ED, Kiseleva R, Greineder CF, Radhakrishnan R, Muzykantov VR: Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine
13 (4): 1495-1506,2017.
Brenner JS: Pulmonary endothelium-targeted liposomes for the treatment for ARDS: Update on technology development of the 2016 BEAR Cage award winning project. American Thoracic Society International Conference, Washington, DC : 2017.
Brenner JS, Pan DC, Myerson JW, Marcos-Contreras OA, Villa CH, Kiseleva R, Cantu E, Muzykantov VR: Nanocarriers adsorbed onto red blood cells massively augment drug delivery to target organs affected by acute critical illness. Am J Respir Crit Care Med 195 : A4367,2017.
Brenner JS: Nanomedicine for the treatment of acute respiratory distress syndrome: the 2016 ATS Bear Cage Award-Winning Proposal Ann Am Thorac Soc 14 (4): 561-564,2017.
Paris AJ, Liu Y, Mei J, Dai N, Guo L, Spruce LA, Hudock KM, Brenner JS, Zacharias WJ, Mei HD, Slamowitz AR, Bhamidipati K, Beers MF, Seeholzer SH, Morrisey EE, Worthen GS: Neutrophils promote alveolar epithelial regeneration by enhancing type II pneumocyte proliferation in a model of acid-induced acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 311 (6): L1062-L1075,2016.